Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 15, 1994Proceedings of the National Academy of SciencesOpen Access

Recombinant human respiratory syncytial virus (RSV)monoclonal antibody Fab is effective therapeutically when introduced directlyinto the lungs of RSV-infected mice.

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJames E. CroweVanderbilt UniversityBMBrian R. MurphyUniversity College DublinRCRobert M. ChanockThe Wistar Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Crowe et al. (1994) studied this question.

synapsesocial.com/papers/6a9599f41fe04514d10f695ahttps://doi.org/10.1073/pnas.91.4.1386
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children1993 · 750 citations
  2. 2A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.1991 · 661 citations
  3. 3Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children1987 · 153 citations
  4. 4AN ANTIGENIC ANALYSIS OF RESPIRATORY SYNCYTIAL VIRUS ISOLATES BY A PLAQUE REDUCTION NEUTRALIZATION TEST11966 · 234 citations